CRIS Current Research Information System

MARTELLI, ALBERTO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.792
EU - Europa 10.069
AS - Asia 9.072
SA - Sud America 741
AF - Africa 678
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 4
Totale 35.380
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.685
SG - Singapore 2.957
GB - Regno Unito 2.633
CN - Cina 2.572
IT - Italia 1.644
VN - Vietnam 1.575
DE - Germania 1.539
SE - Svezia 1.230
HK - Hong Kong 844
UA - Ucraina 573
RU - Federazione Russa 572
IN - India 542
BR - Brasile 513
FR - Francia 422
IE - Irlanda 377
ZA - Sudafrica 240
EE - Estonia 219
NL - Olanda 196
TG - Togo 165
FI - Finlandia 136
JP - Giappone 132
KR - Corea 111
CH - Svizzera 103
CI - Costa d'Avorio 96
SC - Seychelles 94
AR - Argentina 92
JO - Giordania 82
BG - Bulgaria 71
AT - Austria 67
BE - Belgio 65
ID - Indonesia 65
CA - Canada 60
HR - Croazia 57
EC - Ecuador 48
NG - Nigeria 45
MX - Messico 31
GR - Grecia 27
PL - Polonia 26
BD - Bangladesh 25
CL - Cile 25
ES - Italia 24
IR - Iran 24
TR - Turchia 24
CO - Colombia 22
PK - Pakistan 20
AU - Australia 17
UZ - Uzbekistan 15
CZ - Repubblica Ceca 14
RO - Romania 13
LT - Lituania 12
PE - Perù 11
PY - Paraguay 11
LB - Libano 10
MY - Malesia 10
PT - Portogallo 10
HU - Ungheria 9
IQ - Iraq 9
VE - Venezuela 9
MA - Marocco 7
NZ - Nuova Zelanda 7
PH - Filippine 7
UY - Uruguay 7
EG - Egitto 6
TH - Thailandia 6
NP - Nepal 5
SA - Arabia Saudita 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
AM - Armenia 4
DK - Danimarca 4
KE - Kenya 4
MD - Moldavia 4
TW - Taiwan 4
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
MN - Mongolia 3
RS - Serbia 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BF - Burkina Faso 2
BO - Bolivia 2
BS - Bahamas 2
CR - Costa Rica 2
DZ - Algeria 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZM - Zambia 2
Totale 35.363
Salva come PNG Salva come JPEG
Città #
Southend 2.311
Singapore 1.864
Fairfield 1.818
Ashburn 1.454
Chandler 1.002
Woodbridge 913
Houston 856
Hong Kong 833
Santa Clara 824
Wilmington 775
Seattle 766
Cambridge 616
Ann Arbor 614
Princeton 577
Dong Ket 525
Bologna 465
Dublin 375
Boardman 370
Beijing 368
Jacksonville 334
Hefei 290
Nanjing 274
Westminster 253
Ho Chi Minh City 245
Padova 219
Hanoi 214
Los Angeles 183
Berlin 172
Lomé 165
Dallas 157
San Diego 132
Saint Petersburg 125
Jinan 118
Tokyo 118
Helsinki 105
Buffalo 104
New York 102
Shenyang 102
Seoul 100
Abidjan 96
Milan 92
Redondo Beach 87
Turin 87
Frankfurt am Main 82
Amman 81
Bremen 81
Changsha 81
Bern 78
Redmond 78
Mülheim 73
Nanchang 71
Sofia 70
Hebei 67
Brussels 58
Tianjin 55
Guangzhou 53
São Paulo 50
Shanghai 49
Florence 46
Munich 45
Abeokuta 44
Nuremberg 44
Des Moines 43
Jiaxing 42
Dearborn 41
Rome 40
Falkenstein 39
Norwalk 39
Yubileyny 39
Zhengzhou 39
Chicago 38
Medford 37
Washington 37
London 36
Mahé 35
Vienna 34
Haikou 33
Jakarta 33
Falls Church 32
Redwood City 32
Amsterdam 31
Council Bluffs 30
Hangzhou 28
Da Nang 27
Bühl 25
Phoenix 25
Haiphong 24
Ningbo 24
San Francisco 24
Verona 24
Olalla 23
Toronto 23
Kunming 22
Taiyuan 22
Brooklyn 21
Taizhou 21
Udine 21
Wuhan 21
Fuzhou 19
Mountain View 19
Totale 23.549
Salva come PNG Salva come JPEG
Nome #
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 266
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 254
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 238
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 238
INPP4B overexpression and c-KIT downregulation in human achalasia. 227
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 226
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 209
Characterization of biological effects in radiotherapy applications of ultra-high dose rate pulses from a plasma focus device 209
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 206
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 203
Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. 202
The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma 201
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 198
Early biological effects of ultra-high compare to standard dose rate of X-rays on a radioresistant cell line 191
COMBINING DOT1L INHIBITOR EPZ-5676 WITH SORAFENIB TO TREAT MLL-REARRANGED (MLL-R) PEDIATRIC ACUTE MYELOID LEUKEAMIA (AML) 190
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs 188
Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases 186
Therapeutic targeting of CK2 in acute and chronic leukemias. 186
Cancer therapy and treatments during COVID-19 era 185
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. 184
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 183
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 181
Activity of the Selective IκB kinase Inhibitor BMS-345541 against T-Cell Acute Lymphoblastic Leukemia: involvement of FOXO3a 181
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 181
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 180
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 178
Revisiting nuclear phospholipase C signalling in MDS 177
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 177
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 176
Nuclear inositides: facts and perspectives. 175
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 173
Inositide signaling in the nucleus: From physiology to pathology. 173
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 172
Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device 171
Regulation of nuclear phospholipase C activity 169
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 169
Cutting edge: the role of mTOR signaling in laminopathies. 166
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 166
Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes 165
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 165
Quantitative immunodetection of key elements of polyphosphoinositide signal transduction in osteoblasts from arthritic patients shows a direct correlation with cell proliferation 164
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. 164
Advances in Targeting Signal Transduction Pathways. 163
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 162
Nuclear protein kinase C isoforms and apoptosis 161
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 161
Nuclear phospholipase C beta1 and cellular differentiation. 161
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 161
Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells 160
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 160
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 159
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 158
MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia 158
Nuclear inositol lipid metabolism: more than just second messenger generation? 158
Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts 157
Nuclear protein kinase C 156
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine 156
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 155
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction 154
Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. 154
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 153
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells 153
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 153
Antioxidants in the prevention of UVB-induced keratynocyte apoptosis. 152
Signal transduction within the nucleus: Revisiting phosphoinositide inositide-specific phospholipase Cbeta(1). 151
Physiology and pathology of nuclear phospholipase C beta1 151
COMBINAZIONE DI EPZ-5676 E SORAFENIB COME NUOVA STRATEGIA TERAPEUTICA PER IL TRATTAMENTO DELLE LEUCEMIE ACUTE MIELOIDI PEDIATRICHE 151
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway 150
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 150
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 149
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 148
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 147
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia. 146
Significance of subnuclear licalization of key players of inositol lipid cycle. 145
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 145
null 144
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 144
Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. 144
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 143
A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. 143
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 143
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 142
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 142
Pathobiology and therapeutic relevance of GSK-3 in chronic hematological malignancies. 141
PKR Activity Is Required for Acute Leukemic Cell Maintenance and Growth: A Role for PKR-Mediated Phosphatase Activity to Regulate GSK-3 Phosphorylation. 141
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 141
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 140
Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells 140
Nuclear inositide signaling in myelodysplastic syndromes. 139
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias 139
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 139
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 138
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway 138
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 138
Metabolism and signaling activities of nuclear lipids 137
Antiapoptotic role of p38 mitogen activated protein kinase in Jurkat T cells and normal human T lymphocytes treated with 8-methoxypsoralen and ultraviolet-A radiation 137
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 137
Targeting CTLA-4 by its recombinant ligands CD80/CD86: Perspectives towards the development of a novel anti-tumor therapeutic approach. 137
Rabphilin localizes with the cell actin cytoskeleton and stimulates association of granules with F-actin cross-linked by alpha-actinin 136
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 136
Totale 16.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.269
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.047 0 0 0 0 0 159 67 217 287 182 165 970
2021/20225.039 553 135 348 378 446 292 156 352 152 605 808 814
2022/20234.733 547 615 258 680 335 345 211 258 783 88 402 211
2023/20241.371 83 212 123 103 149 290 74 65 43 100 52 77
2024/20255.325 120 849 507 334 1.216 328 372 184 76 229 150 960
2025/20266.230 819 1.217 1.195 848 1.475 676 0 0 0 0 0 0
Totale 36.109